Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-08 in Generalized Myasthenia Gravis
NCT06799247Phase 3Active, not recruiting
- Sponsor
- Cartesian Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 8
01
Overview
A Phase 3 trial of Descartes-08 in myasthenia gravis (MG), sponsored by Cartesian Therapeutics. Started May 2025; status: active, not recruiting.
02
Drugs
Descartes-08
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06799247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06799247.